CXCL2 and neoplasm: After stopping gemcitabine treatment, metastatic tumor cells secrete CXCL1 and CXCL2 to attract neutrophils that express growth arrest-specific 6 (Gas6) protein, a ligand of AXL receptor on metastatic tumor cells, resulting in tumor regrowth and progression.